Avesta Seyidova

  • Citations Per Year
Learn More
BACKGROUND The efficacy of erlotinib is controversial in patients with unknown EGFR mutational status. The aim of this study was to identify the clinicopathological factors that are predictive of erlotinob treatment outcomes for NSCLC patients with unknown EGFR mutational status. MATERIALS AND METHODS A retrospective analysis of 109 patients with advanced(More)
  • 1